Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Authors

Vincent Doré
James D. Doecke
Ziad S. Saad
Gallen Triana-Baltzer
Randy Slemmon
Natasha Krishnadas
Pierrick Bourgeat
Kun Huang
Samantha Burnham
Christopher Fowler
Stephanie R. Rainey-Smith, Edith Cowan UniversityFollow
Ashley I. Bush
Larry Ward
Jo Robertson
Ralph N. Martins, Edith Cowan UniversityFollow
Colin L. Masters
Victor L. Villemagne
Jurgen Fripp
Hartmuth C. Kolb
Christopher C. Rowe

Document Type

Journal Article

Publication Title

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Volume

14

Issue

1

Publisher

Wiley

School

School of Medical and Health Sciences

RAS ID

54178

Funders

National Health and Medical Research Council Enigma Australia

Grant Number

NHMRC Number: APP1132604, APP1140853, APP1152623

Grant Link

https://researchdata.edu.au/big-nhmrc-adnet-app1152623-rowe/1607739/?refer_q=rows=15/sort=score%20desc/class=activity/p=1/q=APP1152623/

Comments

Doré, V., Doecke, J. D., Saad, Z. S., Triana-Baltzer, G., Slemmon, R., Krishnadas, N., . . . Rowe, C. C. (2022). Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), article e12307. https://doi.org/10.1002/dad2.12307

Abstract

Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to 18F-NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F-MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2-fold in Aβ+ CU and 3.5-fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVRMT P =.63 (CI, P =.69; CU, P =.34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ− CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ− PET was 0.89, and for tau+ versus tau− PET was 0.89. Discussion: Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET.

DOI

10.1002/dad2.12307

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.